Exagen Inc. (XGN)
| Market Cap | 262.35M |
| Revenue (ttm) | 41.98M |
| Net Income (ttm) | -16.69M |
| Shares Out | 12.63M |
| EPS (ttm) | -72.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $14.93 |
| Previous Close | $15.50 |
| Change ($) | -0.57 |
| Change (%) | -3.68% |
| Day's Open | 15.50 |
| Day's Range | 14.93 - 15.67 |
| Day's Volume | 20,740 |
| 52-Week Range | 10.29 - 24.67 |
The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to...
Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awarene...
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the...
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today tha...
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten publ...
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 s...
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and othe...
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.18% and 16.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters
Exagen (XGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exagen Inc. (XGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the mark...
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes p...
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnosti...
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...
Record Testing Revenue, Adopters and AVISE CTD® Volumes
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...
Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune disea...
Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript
Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 83.65% year over year to ($0.34), which beat the estim...
Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ne...
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that...
Exagen Showcases Six Scientific Presentations at ACR's First Virtual Annual Meeting in November 2020
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it w...
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the ...
SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune di...
SAN DIEGO, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to annou...
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ...
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced th...
Exagen Inc. (XGN) CEO Ron Rocca on Q2 2020 Results - Earnings Call Transcript
Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63%
AVISE Tests Now Available to 6 Million Humana Military Beneficiaries AVISE Tests Now Available to 6 Million Humana Military Beneficiaries
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced th...
Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it...
SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ...
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2020 Results - Earnings Call Transcript
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2019 Results - Earnings Call Transcript
Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D.
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...
SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmun...
SAN DIEGO, CA, March 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmun...
About XGN
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various conne... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 19, 2019 |
| CEO Fortunato Rocca | Employees 181 |
| Stock Exchange NASDAQ | Ticker Symbol XGN |
Financial Performance
In 2020, Exagen's revenue was $41.98 million, an increase of 3.93% compared to the previous year's $40.39 million. Losses were -$16.69 million, 38.6% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Exagen stock is "Strong Buy." The 12-month stock price forecast is 26.60, which is an increase of 78.16% from the latest price.